IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-677-8022
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.44 million
Profitability
Miscellaneous
Employees95
Next Earnings Date10/29/2019 (Estimated)
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) released its earnings results on Tuesday, October, 30th. The medical equipment provider reported $0.14 EPS for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.04. The medical equipment provider earned $7.62 million during the quarter, compared to the consensus estimate of $7.43 million. Iradimed had a return on equity of 14.78% and a net margin of 23.92%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed issued an update on its third quarter 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share (EPS) guidance of $0.14-0.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $9.7-10 million, compared to the consensus revenue estimate of $9.84 million.
What price target have analysts set for IRMD?
1 brokers have issued 12 month price objectives for Iradimed's shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Iradimed's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 73.4% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
Media coverage about IRMD stock has been trending positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iradimed earned a news impact score of 2.5 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for Iradimed.
Are investors shorting Iradimed?
Iradimed saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 457,700 shares, a decline of 13.2% from the June 30th total of 527,200 shares. Based on an average daily volume of 78,800 shares, the days-to-cover ratio is currently 5.8 days. Currently, 9.3% of the company's stock are sold short. View Iradimed's Current Options Chain.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Luminex (LMNX), Anika Therapeutics (ANIK), Cerus (CERS), AngioDynamics (ANGO), SurModics (SRDX), LeMaitre Vascular (LMAT), Intersect ENT (XENT), Antares Pharma (ATRS), SI-Bone (SIBN), Orthopediatrics (KIDS), OraSure Technologies (OSUR), MiMedx Group (MDXG), GenMark Diagnostics (GNMK), Alphatec (ATEC) and Utah Medical Products (UTMD).
What other stocks do shareholders of Iradimed own?
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
- Mr. Christopher K. Scott, CFO & Sec. (Age 49)
- Mr. John McCreery, Chief Operating Officer (Age 64)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
- Mr. Louis Waldman, Controller (Age 64)
Who are Iradimed's major shareholders?
Iradimed's stock is owned by many different of institutional and retail investors. Top institutional investors include Atria Investments LLC (6.92%), BlackRock Inc. (3.44%), Renaissance Technologies LLC (3.20%), Vanguard Group Inc. (2.43%), RK Capital Management LLC (1.70%) and Mondrian Investment Partners LTD (1.47%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which major investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Acadian Asset Management LLC, Victory Capital Management Inc., Cadence Capital Management LLC, LPL Financial LLC, GSA Capital Partners LLP, Fiera Capital Corp and Wells Fargo & Company MN. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Francis X Casey, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which major investors are buying Iradimed stock?
IRMD stock was acquired by a variety of institutional investors in the last quarter, including Atria Investments LLC, Marshall Wace LLP, RK Capital Management LLC, BlackRock Inc., Mondrian Investment Partners LTD, Renaissance Technologies LLC, Bank of New York Mellon Corp and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Iradimed.
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $20.19.
How big of a company is Iradimed?
Iradimed has a market capitalization of $229.56 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.View Additional Information About Iradimed.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
